Related Experiment Videos
Rationale for immunotherapy of renal cell carcinoma
1Department of Urology, Heinrich-Heine-University, Düsseldorf, FRG.
Abstract:
Metastasis to distant organs is the principal cause of death from renal cell carcinoma (RCC). No commonly accepted therapy is available for disseminated RCC at present. Immunotherapy is a mode of therapy that either interferes with the immune system or makes use of drugs that have been derived from soluble mediators of the immune system. Several lines of evidence suggest that combinations of genetically engineered cytokines (e.g. interleukin-2 and interferon alpha) may be particularly active in the treatment of advanced RCC. There are two major rationales for considering immunotherapy for RCC: (1) there is currently no other therapy available, and (2) there is hardly any innovative approach besides immunotherapy. Still, immunotherapy is far from being a standard therapy for disseminated RCC.
Insights
Advanced renal cell carcinoma (RCC) has limited treatment options. Immunotherapy, using genetically engineered cytokines like interleukin-2 and interferon alpha, shows promise for treating metastatic RCC, though it
Area of Science:
- Oncology
- Immunology
- Internal Medicine
Background:
- Metastasis in renal cell carcinoma (RCC) is a primary cause of cancer-related mortality.
- Currently, no universally accepted therapies exist for disseminated RCC.
- Immunotherapy offers a novel therapeutic strategy for advanced cancers.
Purpose of the Study:
- To explore the potential of immunotherapy, specifically cytokine combinations, for treating advanced renal cell carcinoma.
- To evaluate the rationale for using immunotherapy in cases of disseminated RCC.
- To assess the current standing of immunotherapy as a treatment for advanced RCC.
Main Methods:
- Review of existing evidence on immunotherapy for renal cell carcinoma.
- Analysis of the therapeutic potential of genetically engineered cytokines (e.g., interleukin-2, interferon alpha).
- Examination of the rationale behind immunotherapy use in advanced RCC.
Main Results:
- Genetically engineered cytokines, such as interleukin-2 and interferon alpha, suggest potential efficacy in advanced RCC.
- The lack of alternative therapies and the innovative nature of immunotherapy support its consideration for RCC.
Conclusions:
- Immunotherapy, particularly with cytokine combinations, presents a promising avenue for advanced renal cell carcinoma treatment.
- Despite its potential, immunotherapy is not yet a standard treatment for disseminated RCC.